NCT06739434View on ClinicalTrials.gov

GCB-002 in Treatment of Patients With Rett Syndrome

NAEnrolling by invitationINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

November 11, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2030

Conditions
RETT Syndrome With Proven MECP2 Mutation
Interventions
GENETIC

GCB-002

GCB-002 is a self-complementary AAV9 carrying a full length human MECP2 transgenetic product.

Trial Locations (1)

200092

Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai

All Listed Sponsors
collaborator

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

OTHER

lead

Genecombio Ltd.

OTHER